Anti-epileptic medications are the main treatment option for Lennox-Gastaut Syndrome. The medication is often complicated in case of paediatric disorders as there is risk in development of new-born, due to which various research organizations are focussing on development of therapeutics of Lennox-Gastaut Syndrome.

The growth in therapeutic pipeline of Lennox-Gastaut Syndrome can also be attributed to the upsurge in technical advancements in research, increase in funding by non-profit organization such as National Organization for Rare Disorders as well as availability of limited number of treatments.

Explore Report at: https://www.psmarketresearch.com/market-analysis/lennox-gastaut-syndrome-therapeutics-pipeline-analysis

In January 2017, Takeda Pharmaceutical Company Limited signed a collaborative agreement with Ovid Therapeutics Inc. for the development and commercialization of its investigational new drug candidate, TAK-935, which is selective inhibitor of Cholesterol 24-hydroxylase (CH24H). Currently, the drug candidate is in Phase I/II clinical trial. Under the terms of agreement, Takeda Pharmaceutical Company Limited was to receive an equity in Ovid Therapeutics Inc. for the development milestones of TAK-935. The two companies agreed to share the development and commercialisation cost equally. Takeda Pharmaceutical Company Limited got the rights to lead commercialization in Japan whereas, Ovid Therapeutics Inc. got the commercialization rights in the U.S., Europe, Canada and Israel. In June 2016, Eisai Inc. organized a hackathon called as #HackLGS, in association with Lennox-Gastaut Syndrome (LGS) Foundation, in which technology developers, LGS caregivers, students and creative specialists participated. The purpose of the event was to increase the awareness about the Lennox-Gastaut Syndrome and sharing information about technical innovation that can help to overcome unmet needs for the treatment of the disease.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/lennox-gastaut-syndrome-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of Lennox-Gastaut Syndrome therapeutics include, INSYS Therapeutics Inc., Eisai Inc., GW Research Ltd., Zogenix, Inc., Johnson & Johnson Pharmaceutical Research & Development, LLC, H. Lundbeck A/S, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Ortho-McNeil Pharmaceutical Ltd.